Brookline, MA, United States of America

James Wakefield

USPTO Granted Patents = 10 

Average Co-Inventor Count = 11.8

ph-index = 7

Forward Citations = 442(Granted Patents)


Location History:

  • Arlington, MA (US) (2007)
  • Brookline, MA (US) (1998 - 2010)

Company Filing History:


Years Active: 1998-2010

Loading Chart...
10 patents (USPTO):Explore Patents

Title: Innovations in Amyloid Modulation: The Patents of James Wakefield

Introduction: James Wakefield, an innovative inventor based in Brookline, MA, holds a remarkable portfolio of 10 patents. His contributions are primarily centered on the modulation of amyloid aggregation, a significant area of research with implications for neurodegenerative diseases.

Latest Patents: Among his latest patents, Wakefield has developed novel compounds that either promote or inhibit the aggregation of amyloidogenic proteins and peptides. A groundbreaking invention focuses on modulators of amyloid aggregation that work effectively on natural β-amyloid peptides (β-AP). These compounds are designed to alter the aggregation process or inhibit the neurotoxicity associated with natural β-amyloid peptides when they come into contact with these peptides. Furthermore, his research includes pharmaceutical compositions and diagnostic methods for treating amyloidogenic diseases, marking important advancements in this critical field.

Another noteworthy patent details modulators of β-amyloid peptide aggregation using D-amino acids. These compounds, comprising peptides entirely made of D-amino acids, are particularly effective in controlling the aggregation of natural β-amyloid peptides. This invention not only emphasizes the use of a retro-inverso isomer of β-amyloid peptides but also includes modified amino and carboxy-terminus groups to enhance effectiveness. Through these innovations, Wakefield's work is paving the way for potential breakthroughs in treating amyloid-related conditions.

Career Highlights: Wakefield has built his career at Praecis Pharmaceuticals, Inc., where he has been instrumental in developing these innovative compounds. His work is characterized by a deep understanding of the biochemical pathways involved in amyloid aggregation and a commitment to translating his research into viable therapeutic options.

Collaborations: Throughout his career, James Wakefield has collaborated with respected professionals in the field, including Mark A Findeis and Malcolm L Gefter. These partnerships have further enriched his research and contributions to the understanding of amyloid modulation and treatment.

Conclusion: James Wakefield stands out as a significant figure in the realm of biomedical innovation, particularly regarding amyloid aggregation. His ten patents reflect a dedication to addressing complex health issues through scientific discovery. The work being done at Praecis Pharmaceuticals, Inc. showcases the potential for impactful treatments in the fight against amyloid-related diseases, underscoring Wakefield's importance as an inventor in this vital sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…